作者
Enli Liu,David Marín,Pinaki P. Banerjee,Homer A. Macapinlac,Philip A. Thompson,Rafet Başar,Lucila Nassif Kerbauy,Bethany J Overman,Peter F. Thall,Mecit Kaplan,Vandana Nandivada,Indresh Kaur,Ana Karen Nunez Cortes,Kai Cao,May Daher,Chitra Hosing,Evan N. Cohen,Partow Kebriaei,Rohtesh S. Mehta,Sattva S. Neelapu,Yago Nieto,Michael Wang,William G. Wierda,Michael J. Keating,Richard E. Champlin,Elizabeth J. Shpall,Katayoun Rezvani
摘要
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of the cells is complex. Natural killer (NK) cells that have been modified to express an anti-CD19 CAR have the potential to overcome these limitations.
PDF的下载单位、IP信息已删除
(2025-6-4)
cocolu
柯一一
SYLH
从容芮
眯眯眼的衬衫
jenningseastera
dorianao
自信幻灵
coolkid
yznfly
鸣笛
shiqiang mu
916
OCDer
HEIKU
wy.he
shinysparrow
aldehyde
iNk
Grayball
皖公网安备34019202002308
